Newsletter

Menu

Biocept narrows loss in Q4

By Staff Correspondent |

Biocept (BIOC) narrowed its loss in the fourth quarter, beating analyst estimates. However, sales failed to impress the street. Shares of the firm increased above 3% after the bell as the Q4 loss came in better-than-expected.

Revenue saw a dip of 14% to $860,000 over the prior year, which came in below the Street consensus of $930,000. On a sequential basis, sales improved 7% in the fourth quarter. Net loss surpassed estimates in the Q4 touching $1.43 per share on 4.2 million weighted-average shares outstanding. Analysts were expecting losses for the diagnostics firm to be at $1.58 per share.

Last quarter, Biocept revenues dropped 31.5% to $761,591. However, net loss narrowed to $2.42 per share over $5.90 per share but failed to meet analyst consensus of $2.02 loss per share.

Commenting on the capital requirements CEO Michael Nall said, “We have raised more than $18 million in equity capital since the beginning of 2019, and we now believe that we have the financial resources to implement our business strategy throughout the year.”

Strategic Revamp  

Biocept also plans to launch multi-gene testing panel in the second quarter which is expected to lift the top line in the near future. The company believes that its Target-Selector platform can be commercialized as in vitro diagnostic (IVD) test kits. The platform provides biomarker detection and monitoring ability from patients’ blood sample for better diagnostics.

As part of its strategy, Biocept plans to market the Target-Selector platform to oncologists, pathologists, and physicians who use biomarker details for better diagnostics of their patients. The company plans to make money by offering lab services to biopharma companies to develop cancer drugs using its Target platform. In addition, licensing and sales of in-house testing and technologies to its global partners are also expected to generate revenues.

The diagnostics firm is also expanding its pathology partner program called Empower TC to pathologists throughout the United States. Launched in late 2017, this program helps pathologists to interpret biomarkers from blood samples of cancer patients locally. However, the specimens still need to be sent to its high-tech lab in San Diego, California.

Earlier this week, Biocept expanded its Empower platform to the urology market, which provides the ability to conduct biomarker tests in patients diagnosed with prostate cancer. Investors were upbeat about the news with the stock surging 13% post the announcement.

According to the American Cancer Society, 174,650 new cases are expected to be recorded in the USA for people who are suffering from prostate cancer. The organization also expects the USA to witness 31,620 deaths in 2019 just from patients with prostate cancer.

The early-stage cancer diagnostics company’s stock has increased 46% this year, recovering from the 52-week low levels of $0.66 recorded in December. Biocept’s share has lost about 86% in the last 12 months.

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

 

Advertisement

More on this Company

Thermo-Fisher Q4 2025 Earnings

Thermo Fisher Q4 revenue, earnings beat estimates; stock drops on weak guidance

January 29, 2026
ipo news

Alumis looks to raise $300 million in IPO. Here’s what you need to know

June 25, 2024

Ocean Biomedical co-founder Jack Elias to receive US patent for pulmonary fibrosis treatments

April 20, 2023

221 responses to “Biocept narrows loss in Q4”

  15. fue

    […]we prefer to honor lots of other world-wide-web websites on the internet, even if they aren’t linked to us, by linking to them. Underneath are some webpages worth checking out[…]

  65. morkie dog

    […]we prefer to honor quite a few other world wide web web sites on the net, even when they aren’t linked to us, by linking to them. Underneath are some webpages worth checking out[…]

  98. FiverrEarn

    […]Wonderful story, reckoned we could combine a handful of unrelated information, nonetheless genuinely really worth taking a appear, whoa did one master about Mid East has got more problerms too […]

  111. FiverrEarn

    […]Wonderful story, reckoned we could combine a few unrelated information, nonetheless seriously worth taking a appear, whoa did 1 master about Mid East has got a lot more problerms also […]

  131. Freeze dried

    […]Wonderful story, reckoned we could combine a couple of unrelated information, nonetheless seriously worth taking a appear, whoa did 1 study about Mid East has got additional problerms at the same time […]

  192. candy factory

    […]we prefer to honor a lot of other world wide web web sites on the web, even though they aren’t linked to us, by linking to them. Underneath are some webpages worth checking out[…]

  198. 늑대닷컴

    […]Wonderful story, reckoned we could combine a handful of unrelated data, nonetheless definitely really worth taking a look, whoa did one discover about Mid East has got far more problerms too […]

  203. french bulldog purchase

    […]Wonderful story, reckoned we could combine a handful of unrelated data, nevertheless definitely worth taking a appear, whoa did one particular learn about Mid East has got additional problerms at the same time […]

Leave a Reply

Top